Vaxart Statistics
Total Valuation
Vaxart has a market cap or net worth of $136.30 million. The enterprise value is $100.67 million.
Important Dates
The last earnings date was Wednesday, November 13, 2024, after market close.
| Earnings Date | Nov 13, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Vaxart has 227.44 million shares outstanding. The number of shares has increased by 27.02% in one year.
| Current Share Class | 227.44M |
| Shares Outstanding | 227.44M |
| Shares Change (YoY) | +27.02% |
| Shares Change (QoQ) | +23.15% |
| Owned by Insiders (%) | 0.69% |
| Owned by Institutions (%) | 10.54% |
| Float | 212.27M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 6.46 |
| Forward PS | 10.72 |
| PB Ratio | 1.99 |
| P/TBV Ratio | 2.26 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 6.01 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.83, with a Debt / Equity ratio of 0.34.
| Current Ratio | 0.83 |
| Quick Ratio | 0.78 |
| Debt / Equity | 0.34 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -24.56 |
Financial Efficiency
Return on equity (ROE) is -103.37% and return on invested capital (ROIC) is -47.30%.
| Return on Equity (ROE) | -103.37% |
| Return on Assets (ROA) | -32.91% |
| Return on Capital (ROIC) | -47.30% |
| Revenue Per Employee | $153,761 |
| Profits Per Employee | -$663,651 |
| Employee Count | 109 |
| Asset Turnover | 0.12 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Vaxart has paid $258,000 in taxes.
| Income Tax | 258,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -23.17% in the last 52 weeks. The beta is 0.70, so Vaxart's price volatility has been lower than the market average.
| Beta (5Y) | 0.70 |
| 52-Week Price Change | -23.17% |
| 50-Day Moving Average | 0.78 |
| 200-Day Moving Average | 0.86 |
| Relative Strength Index (RSI) | 32.30 |
| Average Volume (20 Days) | 1,626,589 |
Short Selling Information
The latest short interest is 11.27 million, so 4.96% of the outstanding shares have been sold short.
| Short Interest | 11.27M |
| Short Previous Month | 11.73M |
| Short % of Shares Out | 4.96% |
| Short % of Float | 5.31% |
| Short Ratio (days to cover) | 11.71 |
Income Statement
In the last 12 months, Vaxart had revenue of $16.76 million and -$72.34 million in losses. Loss per share was -$0.40.
| Revenue | 16.76M |
| Gross Profit | -51.38M |
| Operating Income | -71.70M |
| Pretax Income | -75.38M |
| Net Income | -72.34M |
| EBITDA | -62.76M |
| EBIT | -71.70M |
| Loss Per Share | -$0.40 |
Full Income StatementBalance Sheet
The company has $58.71 million in cash and $23.08 million in debt, giving a net cash position of $35.64 million or $0.16 per share.
| Cash & Cash Equivalents | 58.71M |
| Total Debt | 23.08M |
| Net Cash | 35.64M |
| Net Cash Per Share | $0.16 |
| Equity (Book Value) | 68.44M |
| Book Value Per Share | 0.30 |
| Working Capital | -13.91M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$50.94 million and capital expenditures -$406,000, giving a free cash flow of -$51.35 million.
| Operating Cash Flow | -50.94M |
| Capital Expenditures | -406,000 |
| Free Cash Flow | -51.35M |
| FCF Per Share | -$0.23 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -427.81% |
| Pretax Margin | -430.07% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -447.29% |